| CAR-20/19-T Cells / Medical College of Wisconsin, Miltenyi Biotec |
| Recruiting | 1/2 | 100 | US | 8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells | Medical College of Wisconsin | Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Central Nervous System Lymphoma | 01/25 | 01/25 | | |
NCT05990465: LV20.19 CAR T-Cells in Combination with Pirtobrutinib for Relapsed, Refractory B-cell Malignancies |
|
|
| Not yet recruiting | 1 | 12 | NA | Pirtobrutinib, Jaypirca, LOXO-305, LV20.19 CAR T cells | Medical College of Wisconsin | Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Burkitt Lymphoma | 07/26 | 07/27 | | |
| Suspended | 1 | 24 | US | CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells | Medical College of Wisconsin, Children's Hospital and Health System Foundation, Wisconsin | Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia Not Having Achieved Remission, Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia | 06/25 | 06/26 | | |
NCT03375619: Long-term Follow-up Study of Patients Receiving CAR-T Cells |
|
|
| Recruiting | N/A | 500 | US | Long-Term Follow-Up of Participants who Received CAR-T cells | Medical College of Wisconsin | Chronic Lymphocytic Leukemia, Lymphomas Non-Hodgkin's B-Cell, Lymphoma, Small Lymphocytic, Mantle Cell Lymphoma, Central Nervous System Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, Multiple Myeloma | 01/35 | 01/35 | | |
| CAR20.19.22 T / Miltenyi Biotec, Medical College of Wisconsin |
NCT05094206: CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies |
|
|
| Terminated | 1 | 4 | US | 0.75x10^6 cells/kg CAR20.19.22 cells, 1x10^6 cells/kg CAR20.19.22 cells, 2.5x10^6 cells/kg CAR20.19.22 cells, 5x10^6 cells/kg CAR20.19.22 cells, Dose expansion: The maximum tolerated dose of CAR20.19.22 cells | Medical College of Wisconsin, Miltenyi Biotec, Inc. | B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | 01/24 | 01/24 | | |
| CD30 biAb-AATC / Medical College of Wisconsin, Tundra Targeted Therap |
| Not yet recruiting | 1/2 | 42 | US | anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC), CD30 biAb-AATC | Medical College of Wisconsin, Midwest Athletes Against Childhood Cancer | Hodgkin Disease, CD30-Positive Diffuse Large B-Cell Lymphoma, CD30+ Anaplastic Large Cell Lymphoma, CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma, CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma, Leukemia, Lymphoma | 01/27 | 01/27 | | |
